Dr. Ashok Srivastava, M.D., Ph.D., MBA, is the Chief Medical Officer, Senior Vice President Immuno-Oncology, Medical Oncology and Hematology Drug Development, Medical Affairs and Pharmacovigilance for CliniFomatrix. He is also the current Medical Advisor-Vice President of Medical Affairs for Taiho Oncology Inc. Previously he held positions as the Vice President of Oncology Drug Development, Medical Affairs and Clinical Operations for Spectrum Pharmaceuticals, as well as the Executive Medical Director for the Global Oncology Business Unit, Lead Oncology, Global Medical Affairs Oncology for Eisai, Inc.
He has more than 15 years of experience in drug development, medical affairs and commercialization of cancer drugs including radiopharmaceutical and supportive care; Phase I – 4, and marketing commercialization of Hematology, Oncology and radio-immuno-oncology drugs in the USA, EU and Japan. He is a pioneer in cancer drug development worldwide for large and complex Phase 3 Clinical Trials.
Dr. Srivastava is one of the inventors of the Japanese encephalitis vaccine (IXIARO). Dr. Srivastava has published more than 85 papers in National and International Journals, holds more than 120 abstracts, three book chapters and two patents. Amongst his multiple awards and commendations both nationally and internationally, he has been recognized by the United Nations, Ministry of Health, Japan, and Department of Army, Walter Reed Army Medical Center and Walter Reed Army Institute of Research, Washington D.C., USA.
